Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients

Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 3c8b8920f3a000a9c5948e8be6fbb7c92c65e8a6
First added on: Feb 15, 2025